Addex Therapeutics
ADXN
5 hedge funds and large institutions have $96.2K invested in Addex Therapeutics in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0.19% less ownership
Funds ownership: 1.41% → 1.23% (-0.19%)
9% less capital invested
Capital invested by funds: $106K → $96.2K (-$9.48K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GI
GAMMA Investing
Foster City,
California
|
+$1.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$13.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.62K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$271 |
ADXN Hedge Fund Activity: Q1 2025 in Review
5 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q1 2025, worth a combined $96.2K — down 9% from $106K a quarter earlier.
Fund positioning in ADXN was balanced in Q1 2025: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was GAMMA Investing, adding an estimated $1.41K. The largest seller was Morgan Stanley, cutting an estimated $13.9K.
- 5 institutional investors held Addex Therapeutics (ADXN) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $96.2K of Addex Therapeutics stock for Q1 2025, down 9% quarter-over-quarter.
- 0 funds opened new Addex Therapeutics positions in Q1 2025 and 0 closed out.
- The largest Addex Therapeutics buyer in Q1 2025 was GAMMA Investing, an estimated $1.41K added.
- The largest Addex Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $13.9K sold.
Based on aggregated 13F filings for Q1 2025.